Based on current RS Ratings, the strongest Pharmaceuticals & Biotechnology stocks in India are Transchem Ltd. (RS 100), Parmax Pharma Ltd. (RS 100), Gujarat Inject (Kerala) Ltd. (RS 99). These stocks have the highest relative strength compared to all other stocks in the market. RS Rating is updated daily on sharpely. Currently, 54 of 240 stocks (23%) in this group have an RS Rating above 80, placing them in the market's strongest 20%.
Pharmaceuticals & Biotechnology Stocks in India
240 stocks · 2 industriesNSE Industry GroupPart of Healthcare sectorUpdated 9 Aug 2026
Market Statistics
Breadth — stocks above 200 EMA
61%
Strong — 61% above 200 EMA
RS Rating — in market's strongest 20%
54 of 240
23% of stocks are top performers
Average P/E
41.8x
Industry group average
Stocks outperforming Nifty 50 (1Y)
44.6%
Moderate — 44.6% beat Nifty
Current outlook
Auto‑updated dailyThe Pharmaceuticals & Biotechnology industry group shows strong breadth - 61% of 240 stocks above 200 EMA. On the relative strength front, 54 of 240 stocks (23%) carry an RS Rating in the market's strongest 20%, indicating strong relative performance and quality.
From a valuation perspective, fair valuation - the group trades at a average P/E of 41.8x, in line with the sector average of 41.6x. Meanwhile, moderate relative performance — 44.6% of stocks beat Nifty 50 in the last year.
Within the group, Pharmaceuticals shows the strongest breadth at 62% above 200 EMA, while Biotechnology is lagging at 33%. The difference suggests more uniform participation across sub‑industries.
Last updated: 9 Aug 2026 · Based on end‑of‑day data
Top stocks by RS Rating
54 of 240 stocks (23%) are in the market's strongest 20% — showing top 4 stocks by RS Rating
All stocks in Pharmaceuticals & Biotechnology
240 stocks across 2 industries
Stocks
234
P/E
41.6x
ROCE
14.3%
Above 200 EMA
62%
RS Stars
53 of 234
| Company | RS Rating | Market Cap (Cr) | P/E | ROCE % | PAT Margin % | 1Y Return | 200 EMA |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd. | 72 | 4,66,671 | 38.6 | 16.6 | 20.2 | +12.2% | ↑ Yes |
Divis Laboratories Ltd. | 85 | 2,19,676 | 75.1 | 18.8 | 26.0 | +24.4% | ↑ Yes |
Torrent Pharmaceuticals Ltd. | 83 | 1,88,358 | 86.3 | 15.8 | 13.9 | +32.7% | ↑ Yes |
Cipla Ltd. | 65 | 1,18,916 | 35.3 | 14.5 | 11.9 | -5.6% | ↑ Yes |
Zydus Lifesciences Ltd. | 80 | 1,11,142 | 22.1 | 16.2 | 18.6 | +12.0% | ↑ Yes |
Lupin Ltd. | 71 | 1,08,067 | 20.3 | 27.7 | 19.1 | +19.1% | ↑ Yes |
Mankind Pharma Ltd. | 66 | 1,01,432 | 49.7 | 11.9 | 13.9 | -4.6% | ↑ Yes |
Laurus Labs Ltd. | 97 | 99,649.703 | 91.1 | 17.0 | 15.0 | +109.2% | ↑ Yes |
Dr. Reddys Laboratories Ltd. | 45 | 97,593.602 | 30.3 | 11.2 | 9.7 | -9.3% | ↓ No |
Aurobindo Pharma Ltd. | 86 | 95,397.703 | 25.7 | 11.7 | 10.6 | +43.2% | ↑ Yes |
Biocon Ltd. | 74 | 69,445 | 140.2 | 3.5 | 2.9 | +7.3% | ↑ Yes |
Alkem Laboratories Ltd. | 62 | 67,195.5 | 29.2 | 17.4 | 15.6 | +10.2% | ↑ Yes |
Glenmark Pharmaceuticals Ltd. | 69 | 64,316.398 | 39.8 | 35.0 | 9.2 | +5.8% | ↑ Yes |
Abbott India Ltd. | 52 | 59,093.5 | 38.1 | 39.1 | 22.4 | -21.0% | ↑ Yes |
Glaxosmithkline Pharmaceuticals Ltd. | 58 | 44,040.5 | 42.5 | 58.5 | 27.1 | -18.6% | ↑ Yes |
Showing 15 of 234 stocksView all →
Stocks
6
P/E
57.4x
ROCE
19.3%
Above 200 EMA
33%
RS Stars
1 of 6
| Company | RS Rating | Market Cap (Cr) | P/E | ROCE % | PAT Margin % | 1Y Return | 200 EMA |
|---|---|---|---|---|---|---|---|
Anthem Biosciences Ltd. | 81 | 47,364.699 | 82.2 | 24.9 | 28.8 | +9.1% | ↑ Yes |
Advanced Enzyme Technologies Ltd. | 59 | 3,631.94 | 21.5 | 11.8 | 22.6 | -7.0% | ↓ No |
CCME Global Ltd. | — | 385.304 | — | -3.1 | — | — | ↓ No |
Vivo Bio Tech Ltd. | 10 | 48.376 | — | 7.0 | -5.2 | -32.9% | ↓ No |
Shree Ganesh Bio-Tech (India) Ltd. | 27 | 21.924 | -56.8 | -1.5 | -6.0 | -30.4% | ↓ No |
Showing 5 of 6 stocksView all →
Showing 2 of 2 industriesExplore complete stock list with fundamentals & technical data
Explore Pharmaceuticals & Biotechnology →Market breadth breakdown
Percentage of stocks in this group meeting each technical condition — updated daily
Above 200 EMA
61%
Above 200 SMA
64%
Above 50 EMA
62%
Above 50 SMA
61%
Outperf Nifty 50 (1Y)
45%
Outperf Nifty 50 (6M)
84%
Outperf Nifty 50 (3M)
61%
RSI above 70
10%
RSI below 30
4%
Near 52W High
32%